Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
EudraCT number 2018-003395-12
Protocol number ASTX727-02
Sponsor Astex Pharmaceuticals, Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, CA,94588, United States of America
Indications Hemato-oncology
Diagnosis Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 9.3.2020
Date of approval by EC 4.12.2019
Date of initiation CT in ČR 24.8.2020
Date of ending CT in ČR
Sites Fakultní nemocnice Brno,Interní hematologická a onkologická klinika,Jihlavská 20,Brno,625 00
Fakultní nemocnice Královské Vinohrady,Interní hematologická klinika,Šrobárova 1150/50,Praha 10,100 34

‹‹ Back to list